Ephrin receptor 7 is a protein of EphA7 encoded by genes in humans. This gene belongs to the ephrin receptor subfamily of protein tyrosine kinase. In the central nervous system, EPH-related receptors EPH is involved in mediating a particular developmental event. Usually, EPH subfamily receptors, have an extracellular region containing two fibronectin type III repeats and cysteine-rich domain and kinase domain of the single. Are divided into two groups based on the similarity of their affinity for the ligand ephrin binding and ephrin-AB extracellular domain sequence of the ephrin receptor.

This gene belongs to the ephrin receptor subfamily of protein tyrosine kinase. In the central nervous system, EPH-related receptors EPH is involved in mediating a particular developmental event. Usually, EPH subfamily receptors, have an extracellular region containing two fibronectin type III repeats and cysteine-rich domain and kinase domain of the single. Are divided into two groups based on the similarity of their affinity for the ligand ephrin binding and ephrin-AB extracellular domain sequence of the ephrin receptor.

Available ligand is known as (pronounced EFF-rinse) ephrin that it is possible to obtain as an abbreviation for teracting family eceptor, Greek εφoρos which means the controller and director and protein (ephoros). Naturally, glycosylphosphatidylinositol-anchored membrane or as (GPI) linked ligands are divided into the type of two structures or through a transmembrane domain. Further, subgroups of these two ligands, may order, as described below, on the basis of the preferential binding to two receptor subgroup are separated based on a functional relationship. Therefore, it is divided into ephrin-B subclass is a transmembrane protein ephrin subclass, and a GPI-binding protein, the ligand has been proposed. Places of the human gene map position of these two groups is (specify in advance EPLG) EFNB and EFNA.

This gene belongs to the ephrin receptor subfamily of protein tyrosine kinase. In the central nervous system, EPH-related receptors EPH is involved in mediating a particular developmental event. The receptor in EPH Subfamily has an extracellular region containing two fibronectin type III repeats and a cysteine-rich domain and the kinase domain of a single, typically. Are divided into two groups based on the similarity of their affinity for the ligand ephrin binding and ephrin-AB extracellular domain sequence of the ephrin receptor.

In the contact-dependent bidirectional signaling device to adjacent cells, and as a result, random GPI-anchored ephrin present in the cell in the adjacent – receptor tyrosine kinase that binds the family ligand. Downstream between signaling pathways ligand ephrin reverse signaling is called downstream signaling the first signaling path of the receptor. Of the GPI-anchored ephrin ligand interaction with the function / Related ligand for EFNA5 of EphA7 is, cells develop regulation of the brain – to adjust the repulsive force and cell adhesion. Involved in the management of appropriate topographic map of retinal axon hill cortex and thalamus axons, such as avoidance and activity of the axon there. In addition, you can adjust the development of the brain by caspase (CASP3)-dependent pro-apoptotic activity. Forward signaling can lead to activation of the components of the ERK signaling pathway, including MAPK3 and MAP2K1, MAP2K2, MAPK1 that is phosphorylated upon activation of the EphA7

There is a possibility that a comprehensive study on the genetics of cancer will lead to treatment options. By referring to the chromosomal changes, unbiased genetic screen to identify the (EphA7) ephrin receptor A7 as a tumor suppressor follicular lymphoma (FL). Inactivated at 72% of the FLS and subject to deletion of 6Q EphA7. Knock down the drive lymphoma development of Florida EphA7 in a mouse model. As well as the physiological function of those in the development of brain, soluble splice variant of the EphA7 (EPHA7TR) is reacted with carcinogenesis signal in block lymphoma cells and Eph receptor other. Thus, as drug activity, application of the protein EPHA7TR the purified to produce an anti-tumor effect against transplanted human lymphoma. In addition, it is possible to target the tumor suppressor lymphoma in vivo directly (rituximab) through the merger EPHA7TR of anti-CD20 antibody. It demonstrates the power of combining the description tumor genomics the functional screen, our study reveals a EPHA7TR as a tumor suppressor and the possibility of immediate medical attention.

Compared with five cell lines and colon (p = 0.008), were normal mucosa corresponding significant reduction in the expression of EphA7 in human colon cancer, a semi-quantitative reverse transcription polymerase chain reaction assay in 59 colon cancer tissues intestine were measured using. To investigate the mechanism of suppression of colorectal cancer EphA7, to examine the methylation of the 5’CpG island of the position translation start in five cell lines from colorectal cancer using restriction enzymes and bisulfite sequencing and methylation-specific PCR Te, and found evidence of abnormal methylation. EphA7 expression in colon cancer cell lines, 5 – were harvested after treatment with aza-2′-deoxycytidine. Analysis of methylation in tumors of total 75, more men than differentiation that hypermethylation of colorectal cancer compared with well-differentiated adenocarcinoma moderately and women as compared with clinicopathological parameters It is common, but it became clear. Methylation trend in rectal cancer was observed, it is more common than colon. Hypermethylation is observed in colorectal adenomas. This is the first report describing the suppression of Ephesus of the gene family in solid tumors by methylation abnormal 5’CpG the island. It provides evidence that gene is incorporated said EphA7 in human colon carcinogenesis.